Blog

Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18
Drug Discovery & Development, Synthetic & Medicinal Chemistry, Artificial Intelligence in Pharma, Metabolic & Endocrine Therapeutics, Clinical Trials & Regulatory Insights, Pharmaceutical Innovation My Cao Drug Discovery & Development, Synthetic & Medicinal Chemistry, Artificial Intelligence in Pharma, Metabolic & Endocrine Therapeutics, Clinical Trials & Regulatory Insights, Pharmaceutical Innovation My Cao

Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18

ChemAIRS revolutionized the synthesis of Eli Lilly’s oral GLP-1 agonist Orforglipron—optimizing key intermediates and streamlining scale-up conditions for commercial-ready production. Accelerate your metabolic drug development with AI-driven retrosynthesis.

Read More